DEA's July 2026 7-OH Notice of Intent: What Has and Has Not Changed

DEA's July 2026 announcement started two federal tracks that now have different statuses. MGPI, MGM-15, and MGM-16 were temporarily placed in Schedule I on August 26; the separate threshold action for 7-OH remains proposed as of September 19, 2026.

MGPI, MGM-15, and MGM-16

DEA's temporary order placed mitragynine pseudoindoxyl, MGM-15, and MGM-16 in Schedule I from August 26, 2026 through August 26, 2028, unless extended or replaced sooner. DOJ described narrow enforcement discretion for incidental trace MGPI; MGPI remains Schedule I, and the policy does not cover MGM-15 or MGM-16.

The separate 7-OH threshold proposal

DEA's separate notice proposes control of botanical material containing more than 0.050% 7-OH on a dry-weight basis and specified processed or synthetic articles containing more than 0.050% or more than 1mg in the article. HHS accepted comments on the threshold through September 10. No effective temporary order for that proposal was located for this update.

Where the 7-OH proposal stands

• It did not make every material described as kratom a federal Schedule I substance.
• It did not make mitragynine identical to 7-OH, MGPI, MGM-15, or MGM-16.
• It did not settle FDA status, state law, or a store's delivery policy.
• It did not turn a brand name into reliable evidence of composition.

What customers can verify

Check the exact active compound, physical form, amount basis, ingredients, lot or sample ID, and lab results. Then verify the newest Federal Register publication and destination-specific rules. Kratom Paradise does not sell synthetic/concentrated 7-OH, MGPI, MGM-15, or MGM-16.

See the dated federal status table · Review current state shipping restrictions

Sources and further reading

• August 26 temporary order
• DEA July 1, 2026 announcement
• Federal Register notice for 7-OH above specified thresholds
• July notice for mitragynine pseudoindoxyl, MGM-15, and MGM-16
• HHS extension for comments on the proposed 7-OH threshold
• FDA consumer information about enhanced 7-OH products
• FDA and Kratom
• Human opioid-receptor pharmacology of mitragynine and 7-OH
• Metabolism of mitragynine to 7-OH
• Clinical case report involving a semi-synthetic 7-OH product